Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.

Levy V, Grant RM.

Clin Infect Dis. 2006 Oct 1;43(7):904-10. Epub 2006 Aug 23. Review. Erratum in: Clin Infect Dis. 2006 Nov 15;43(10):1376.

2.

Antiretroviral therapy and HIV/hepatitis B virus coinfection.

Benhamou Y.

Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S98-103.

3.

[Hepatitis B in patients with HIV infection].

Barreiro P, Martín-Carbonero L, García-Samaniego J.

Enferm Infecc Microbiol Clin. 2008 May;26 Suppl 7:71-9. Review. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2008 Dec;26(10):675.

PMID:
19100234
4.

Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.

Kosi L, Reiberger T, Payer BA, Grabmeier-Pfistershammer K, Strassl R, Rieger A, Peck-Radosavljevic M.

J Viral Hepat. 2012 Nov;19(11):801-10. doi: 10.1111/j.1365-2893.2012.01601.x. Epub 2012 Mar 15.

PMID:
23043387
5.

Hepatitis B virus treatment in HIV-infected patients.

Thio CL.

Top HIV Med. 2006 Dec-2007 Jan;14(5):170-5.

6.

[Long-term therapy for chronic hepatitis B in HIV co-infected patients].

Pais R, Benhamou Y.

Gastroenterol Clin Biol. 2010 Sep;34 Suppl 2:S136-41. doi: 10.1016/S0399-8320(10)70033-6. French.

7.

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.

Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, Ruxrungtham K, Dore GJ.

Hepatology. 2008 Oct;48(4):1062-9. doi: 10.1002/hep.22462.

PMID:
18697216
8.

The impact of human immunodeficiency virus on viral hepatitis.

Mallet V, Vallet-Pichard A, Pol S.

Liver Int. 2011 Jan;31 Suppl 1:135-9. doi: 10.1111/j.1478-3231.2010.02394.x. Review.

PMID:
21205151
9.

Hepatitis B in HIV patients: what is the current treatment and what are the challenges?

Soriano V, Tuma P, Vispo E, Labarga P, Fernández JV, Medrano J, Barreiro P.

J HIV Ther. 2009 Mar;14(1):13-8.

PMID:
19731560
10.

Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.

Lewin SR, Ribeiro RM, Avihingsanon A, Bowden S, Matthews G, Marks P, Locarnini SA, Ruxrungtham K, Perelson AS, Dore GJ.

Hepatology. 2009 Apr;49(4):1113-21. doi: 10.1002/hep.22754.

11.

Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.

Gaglio PJ, Sterling R, Daniels E, Tedaldi E; Terry Beirn Community Programs for Clinical Research on AIDS Hepatitis Working Group.

Clin Infect Dis. 2007 Sep 1;45(5):618-23. Epub 2007 Jul 30.

12.

HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.

Hamers RL, Zaaijer HL, Wallis CL, Siwale M, Ive P, Botes ME, Sigaloff KC, Hoepelman AI, Stevens WS, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82. doi: 10.1097/QAI.0b013e3182a60f7d.

PMID:
23892239
13.

Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.

Alvarez-Uria G, Ratcliffe L, Vilar J.

HIV Med. 2009 May;10(5):269-73. doi: 10.1111/j.1468-1293.2008.00683.x. Epub 2009 Feb 5.

14.

Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.

Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM.

J Viral Hepat. 2007 Mar;14(3):176-82.

PMID:
17305883
15.

In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.

Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.

Antivir Ther. 2004 Jun;9(3):353-63.

PMID:
15259898
16.
17.

Treatment of HIV/HBV coinfection: clinical and virologic issues.

Thio CL, Locarnini S.

AIDS Rev. 2007 Jan-Mar;9(1):40-53. Review.

PMID:
17474312
18.

Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.

Matthews GV, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, Sasadeusz J, Revill PA, Littlejohn M, Hoy JF, Finlayson R, Ruxrungtham K, Saulynas M, Locarnini S, Thio CL.

Clin Infect Dis. 2013 May;56(9):e87-94. doi: 10.1093/cid/cit002. Epub 2013 Jan 11.

19.

Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.

Audsley J, Arrifin N, Yuen LK, Ayres A, Crowe SM, Bartholomeusz A, Locarnini SA, Mijch A, Lewin SR, Sasadeusz J.

HIV Med. 2009 Apr;10(4):229-35. doi: 10.1111/j.1468-1293.2008.00675.x. Epub 2009 Jan 28.

20.

Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.

Quiros-Roldan E, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, Zaltron S, Puoti M, Carosi G, Torti C.

Antivir Ther. 2008;13(3):341-8.

PMID:
18572746
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk